Sangamo BioSciences | SGMO - Процентные расходы





Процентные расходы Изменить Дата
Alaunos Therapeutics USD 1.07M 215K 2023-06
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amgen USD 657M 4M 2026-03
Bayer EUR 675M 87M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Cipla INR 140.3M 8.5M 2025-12
Compugen USD 954K 116K 2025-09
CSL USD 215M 111M 2025-12
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 167M 21M 2026-03
Grifols EUR 156.07M 31.46M 2025-09
Ionis Pharmaceuticals USD 17M 1000K 2026-03
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
Merck USD 479M 67M 2026-03
Novartis USD 343M 39M 2026-03
Omeros USD 4.05M 5.16M 2024-09
Pfizer USD 711M 59M 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 178M 203M 2026-03
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Tectonic Therapeutic USD 12K 276.99M 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12